Welt S - Search Results

1

Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.

Barendswaard EC, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM, Larson SM, Welt S. Barendswaard EC, et al. Among authors: welt s. J Nucl Med. 2001 Aug;42(8):1251-6. J Nucl Med. 2001. PMID: 11483688 Free article.

2

Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.

Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, Larson SM, Old LJ. Divgi CR, et al. Among authors: welt s. J Nucl Med. 2004 Aug;45(8):1412-21. J Nucl Med. 2004. PMID: 15299069 Free article. Clinical Trial.

3

Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy.

O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. O'Donoghue JA, et al. Among authors: welt s. Cancer Biother Radiopharm. 2002 Aug;17(4):435-43. doi: 10.1089/108497802760363222. Cancer Biother Radiopharm. 2002. PMID: 12396707

4

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.

Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF, et al. Welt S, et al. J Clin Oncol. 1994 Aug;12(8):1561-71. doi: 10.1200/JCO.1994.12.8.1561. J Clin Oncol. 1994. PMID: 8040668 Clinical Trial.

5

Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.

Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, Larson SM, Old LJ, et al. Welt S, et al. J Clin Oncol. 1994 Jun;12(6):1193-203. doi: 10.1200/JCO.1994.12.6.1193. J Clin Oncol. 1994. PMID: 8201382 Clinical Trial.

6

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, et al. Oosterwijk E, et al. Among authors: welt s. J Clin Oncol. 1993 Apr;11(4):738-50. doi: 10.1200/JCO.1993.11.4.738. J Clin Oncol. 1993. PMID: 8478666 Clinical Trial.

7

Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.

Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ. Welt S, et al. J Clin Oncol. 1996 Jun;14(6):1787-97. doi: 10.1200/JCO.1996.14.6.1787. J Clin Oncol. 1996. PMID: 8656247 Clinical Trial.

8

Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody.

Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, McGuffie E, Old LJ, Larson SM. Daghighian F, et al. Among authors: welt s. J Nucl Med. 1996 Jun;37(6):1052-7. J Nucl Med. 1996. PMID: 8683300 Free article.

9

Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).

Tschmelitsch J, Barendswaard E, Williams C Jr, Yao TJ, Cohen AM, Old LJ, Welt S. Tschmelitsch J, et al. Among authors: welt s. Cancer Res. 1997 Jun 1;57(11):2181-6. Cancer Res. 1997. PMID: 9187118 Clinical Trial.

10

Antibody-based immunological therapies.

Scott AM, Welt S. Scott AM, et al. Among authors: welt s. Curr Opin Immunol. 1997 Oct;9(5):717-22. doi: 10.1016/s0952-7915(97)80054-4. Curr Opin Immunol. 1997. PMID: 9368782 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters